Mylatabi (Eltrombopag)

Eltrombopag acts as a thrombopoietin receptor agonist. It binds to the c‑Mpl receptor on megakaryocyte precursors, activating intracellular JAK/STAT signaling. This stimulation promotes the proliferation and maturation of megakaryocytes, leading to increased platelet formation in the bone marrow.

The dosage of Mylatabi is individualized and must be determined by a qualified prescriber based on the patient’s condition, laboratory values, and response to therapy. Clinicians adjust the dose to achieve target platelet levels while monitoring safety parameters.

Safety data for eltrombopag in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Mylatabi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative to eltrombopag is romiplostim, another thrombopoietin receptor agonist administered by subcutaneous injection. Eltrombopag is taken orally, which may be more convenient for some patients, whereas romiplostim requires weekly injections. Both agents aim to raise platelet counts, but their pharmacokinetic profiles, dosing schedules and side‑effect spectra differ.

Mylatabi should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Mylatabi is administered orally, typically as a tablet taken with a low‑fat meal to improve absorption. Patients should follow the prescriber’s instructions regarding timing, food intake, and any necessary precautions such as avoiding certain antacids.

Serious risks include hepatotoxicity, which may manifest as significant elevations in liver enzymes or liver injury, and thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Rarely, patients may develop severe skin reactions like Stevens‑Johnson syndrome or bone‑marrow fibrosis. Prompt monitoring and reporting of symptoms are essential.

Mylatabi is contraindicated in patients with known hypersensitivity to eltrombopag or any of its excipients. Caution is advised for individuals with active liver disease, uncontrolled infections, or a history of thromboembolic disorders. Pregnant or breastfeeding women should only use it when clearly indicated by a physician.